Ultraviolet-shielding type patch

ABSTRACT

With the purpose of providing patches which do not cause photodecomposition of drugs even when exposed to the direct rays of the sun and which exhibit satisfactory drug effects and are excellent in physical properties and stability of pharmaceutical preparations, the invention provides a patch comprising a polyester substrate and a pressure-sensitive adhesive layer formed on one surface of the substrate and containing a nonsteroidal anti-inflammatory drug (NSAID) wherein the substrate contains a hydroxyphenylbenzotriazole derivative represented by the general formula (1):  
                 
 
wherein R 1  and R 2  are each independently hydrogen or C 1-8  alkyl; and X is halogen atom.

DETAILED DESCRIPTION OF THE INVENTION

1. Technical Field

The invention relates to a patch which is excellent inultraviolet-shielding effect.

2. Background Art

Since a patch is used by sticking it on a skin surface, in outdoorsthere is a case that it receives irradiation of sunrays depending on itsapplication part. Therefore, in a patch containing a compound which iseasily decomposed by ultraviolet from the sun, there are problems inwhich an original drug effect cannot be exhibited due to decompositionof a drug in base or its photodecomposition products induce a sideeffect or the like.

Conventionally, as means to avoid such side effects due to ultraviolet,it has generally been tried to add an ultraviolet absorbent in abase.For example, although there was an external preparation to suppress thephotodedecomposition of an efficacious ingredient by blending anultraviolet absorbent in a base (ex. see Patent document 1), there was aproblem that the safety was feared because the ultraviolet absorbentitself was contacted and absorbed. In addition, a method to contain anultraviolet absorbent in a backing of a patch has been proposed (ex. seePatent documents 2 and 3). There is a percutaneous absorption patchhaving a laminate as a backing, which consists of not less than twolayers, and consisting of a resin film in which at least one layer ofsaid laminate contains an ultraviolet absorbent (ex. see Patent document4). Further, a patch is disclosed in which the photo-stability of a drugis increased by a monolayer backing treated with an organic ultravioletabsorbent and/or an inorganic ultraviolet absorbent (ex. see Patentdocument 5).

However, although in these the effect to shield ultraviolet rayirradiated from artificial lights such as a mercury lamp and a roomlight is recognized, these are insufficient to suppress enough thephotodecomposition of a drug occurring in case of being exposed to thedirect rays of the sun in a season when an ultraviolet dose is high, andfurther, there were the demerits that auxiliary devices such as coveringa patch by clothing or by a protecting cover was necessary.

Patent document 1: JP, B, 5-8169

Patent document 2: JP, B, 3-76285

Patent document 3: JP, U, 5-30118

Patent document 4: JP, A, 10-265371

Patent document 5: WO 01/68061

DISCLOSURE OF THE INVENTION PROBLEMS TO BE SOLVED BY THE INVENTION

Consequently, the object of the invention is to provide patches which donot cause photodecomposition of drugs even when exposed to the directrays of the sun in a season of high ultraviolet dose and which exhibitsatisfactory drug effects and are excellent in physical properties andstability of pharmaceutical preparations.

MEANS TO BE SOLVE THE PROBLEMS

During extensive research to solve the above problems, the inventorsfound that by an ultraviolet shielding treatment of apolyester-stretching backing with a specific hydroxyphenylbenzotriazolederivative, photodecomposition of a drug in a patch can extremely besuppressed and completed the invention.

Namely, the invention relates to a patch comprising a polyester backingand a pressure-sensitive adhesive layer formed on one surface of thebacking and containing a nonsteroidal anti-inflammatory drug (NSAID)wherein the backing contains a hydroxyphenylbenzotriazole derivativerepresented by the general formula (1):

(1) wherein R₁ and R₂ are each independently hydrogen or C₁₋₈ alkyl; andX is halogen atom.

In addition, the invention relates to the patch, wherein the backingcontains further titanium oxide.

Further, the invention relates to the patch, wherein the ultraviolettransmittance of the backing is not more than 2%.

In addition, the invention relates to the patch, wherein the weight ofthe backing is 100 g/m²-130 g/m².

Further, the invention relates to the patch, wherein the nonsteroidalanti-inflammatory drug (NSAID) is ketoprofen.

In addition, the invention relates to the patch, wherein thepressure-sensitive adhesive layer consists of a styrene-isoprene-styreneblock polymer and/or polyisobutylene.

Further, the invention relates to the patch, wherein thepressure-sensitive adhesive layer contains no ultraviolet absorbent.

EFFECT OF THE INVENTION

By treatment of a polyester backing with a specific benzotriazoleultraviolet absorbent, a patch of the invention can surprisingly lowerthe ultraviolet transmittance of the backing, exhibiting satisfactorydrug effects even when exposed to the direct rays of the sun in a seasonof high ultraviolet dose. Therefore, it can favorably be used for anonsteroidal anti-inflammatory drug (NSAID) which is low in stabilitytoward ultraviolet. In addition, even when a pressure-sensitive adhesivelayer contains no ultraviolet absorbent, it has no degradation of thepressure-sensitive adhesive layer and is excellent in stability and alsois excellent in safety due to no contact to the skin of an ultravioletabsorbent itself.

In a patch of the invention, the ultraviolet transmittance of a backingis preferably not more than 2% under the condition that the ultravioletintensity is 3 mW/cm². Further, as to the above ultraviolet dose, changeby a season and area is recognized, and as one example, a daytimeultraviolet intensity on Aug. 22, 2002 in Tosu-shi, Saga prefecture wasmeasured, showing 2.9 mW/cm² and 81936 mJ/cm² of the accumulatedultraviolet dose per day, and to the contrary the ultraviolet intensityin the same area on Nov. 5, 2002 was 1.6 mW/cm² and 47340 mJ/cm² of theaccumulated ultraviolet dose. That is, the patch of the invention canunusually lower the ultraviolet transmittance even under the strongultraviolet intensity in a season of high ultraviolet dose.

BEST EMBODIMENT FOR CARRYING OUT THE INVENTION

The patch of the invention can be used mainly as a plaster (a tapepreparation).

The patch of the invention is made to contain a benzotriazoleultraviolet absorbent which is adsorbed, absorbed or fixed to apolyester backing, or is incorporated in fibers consisting of thebacking. The benzotriazole ultraviolet absorbent on the above inventionis a benzotriazole derivative represented by the formula (1), wherein R₁and R₂ represent hydrogen or lower alkyl groups, preferably C₁-C₈ alkylgroups in view of easy treatment of the polyester backing, morepreferably methyl or t-butyl.

X represents a halogen atom, preferably fluorine, bromine or chlorine,in particular preferably chlorine in view of easy treatment of thepolyester backing.

In addition, R₁ and R₂ may be same or different.

Specifically, the following compounds are illustrated. That is,illustrative are2-(3-t-butyl-5-methyl-2-hydroxyphenyl)-5-chlorobenzotriazole,2-(3,5-di-t-butyl-2-hydroxyphenyl)-5-chlorobenzotriazole, etc.

As for an ultraviolet shielding treatment using these benzotriazoleultraviolet absorbents, a method to adsorb, absorb or fix saidabsorbents to fibers or cloth is used, which are the material of abacking for the patch, consisting of monolayer. In addition, in aproduction step of fibers which are the above backing material(polymerization or fiber forming steps), polymer is reformed by additionor incorporation with said absorbent, and then the reformed polymermaybe used as a material for the backing by fiber formation.

The content of these benzotriazole ultraviolet absorbents in a backingis preferably 0.01-20% by mass against the total mass of the backing(containing the absorbent), more preferably 0.05-5% by mass, furtherpreferably 1-2% by mass.

Further, in order to obtain an ultraviolet-shielding effect of thebacking used in the invention, it may be treated with a metal oxidewhich is an ultraviolet-shielding agent, and specifically, one or morespecies selected from titanium oxide, zinc oxide, ferric oxide, talc,kaolin, alumina and calcium carbonate can be blended. In particular,treatment using titanium oxide is preferable.

As an ultraviolet screening treatment using these inorganic shieldingagents, a method of fiber formation after reforming by addition orincorporation of the inorganic shielding agents into polymer isgenerally used in the production step of fibers (polymerization or fiberforming steps).

The content is preferably 0.1-20% bymass against the total mass of thebacking, more preferably 0.5-10% by mass, and the shielding effecttoward ultraviolet can satisfactorily be exhibited by these blendratios.

The material of the backing is a polyester cloth, and specifically,illustrative are polyethylene terephthalate, etc. These can be used bytreatment into woven fabric, knitted fabric, non-woven fabric, film orthe like.

The weight of the backing is preferably 100 g/m²-130 g/m², morepreferably 105 g/m²-120 g/m² considering the transmittance ofultraviolet and use feeling toward the skin.

The ultraviolet transmittance of the backing used in the invention ispreferably not more than 2.0%, more preferably not more than 1.5%,further preferably not more than 1.0% under the condition of 3.0 mW/cm²of ultraviolet intensity. Further, as for measurement of the ultravioletintensity, an ultraviolet intensity meter (Topcon Co., Ltd., UVR-2) isused, and UD-36 is used for a receiving part, whereby the measuring wavelength is 310-400 nm. As for the calculation of the ultraviolettransmittance, an ultraviolet dose transmitting through the backing ismeasured under a circumstance in which a direct sunlight irradiatesenough to the backing, and the ultraviolet intensity without the abovepreparation is made 100, calculating each transmittance.

As for the nonsteroidal anti-inflammatory drugs (NSAID) used in thepatch of the invention, ketoprofen, diclofenac, suprofen, piroxicam,indomethacin, flurbiprofen, felbinac, loxoprofen, ibuprofen, ketorolac,naproxen, benoxaprofen, carprofen, fenorofen, or salts thereof, and oneor more of these drugs can be blended. Among these nonsteroidalanti-inflammatory drugs, ketoprofen is most appropriate. The blend ratioof the nonsteroidal anti-inflammatory drug is 0.01-30% bymass based onthe total amount of the base containing the drug, preferably 0.1-16% bymass, including a form of a medically acceptable inorganic salt ororganic salt, and satisfactory drug effects can be expected by thisblend ratio.

As for the base used in the patch of the invention, a rubber base ispreferable, and as a rubber base, illustrative are polyisoprene rubber,polyisobutylene rubber, natural rubber, styrene-butadiene-styrene blockcopolymer, styrene-isoprene-styrene block copolymer, styrene-butadieneblock copolymer, styrene-isoprene block copolymer,styrene-isoprene-butadiene block copolymer,styrene-ethylene-propylene-styrene block copolymer and the like assynthetic rubbers or natural rubbers.

Further, since styrene-isoprene-styrene block copolymer is easilydegradable against ultraviolet and is poor in photo-stability, thebacking used in the invention can be favorably used. In case of usingstyrene-isoprene-styrene block copolymer, the average molecular weightis preferably 100,000-300,000, and illustrative are, for example, KRATOND-KX401CS or D-1107CU manufactured by (Shell Chemical Co., Ltd.),SIS-5000 or SIS-5002 (manufactured by JSR Co., Ltd.), Quintac 3530, 3421or 3570C (Zeon Co., Ltd.) and Solprene 428 (PHILLIPS PETROLEUM Co.,Ltd.). As for the base, one or more of these styrene-isoprene-styreneblock copolymers can be blended, and the content is preferably 10-50%bymass based on the total amount of the base considering theagglutinative strength and workability, more preferably 13-40% by mass,further preferably 15-30% by mass.

As to the base of the patch of the invention, sticking properties to theskin, a pain at the time of release, a rash on the skin and the like aregreatly improved by containing styrene-isoprene-styrene block copolymerwith the above average molecular weight at the above blend ratio andmore preferably by adjusting further the viscosity and the adhesivestrength.

In addition, the base of the patch of the invention may be blended withpolyisobutylene, and the content is preferably 1-50% by mass based onthe total amount of thebase, more preferably 5-40% bymass. Further, twoor more species of polyisobutylenes with a different average molecularweight may be used in combination, and,for example, the combination ofpolyisobutylene of viscosity average molecular weight (Staudingermethod) of 5,000-15,000 and polyisobutylene of viscosity averagemolecular weight of 50,000-200,000 is preferable. Furthermore, blendingof these polyisobutylenes at a specific ratio is further preferable.

As polyisobtylene of viscosity average molecular weight of 5,000-15,000illustrative are Vistanex LM-MS and LM-MH (manufactured by ExxonChemical Co., Ltd.), Tetrax 4T, 5T and 6T (manufactured by Nihon SekyuKagaku Co., Ltd.), Oppanol B12SF and B15SF (manufactured by BASF JapanCo., Ltd.), etc., and one or more of these can be blended in a base of atape preparation. The content is preferably 1-50% by mass based on thetotal amount of the base, more preferably 5-30% by mass.

As polyisobtylene of viscosity average molecular weight of50,000-200,000 illustrative are Vistanex MML-80, MML-100, MML-120 andMML0140 (manufactured by Exxon Chemical Co., Ltd.), Opanol B-80, B-100,B-120 and B-150 (manufactured by BASF Japan Co., Ltd.), etc., and one ormore of these can be blended in abase of a tape preparation. The contentis preferably 0.1-40% by mass based on the total amount of the base,more preferably 1-30% by mass, and by these blend ratio and morepreferably further by adjustment of the viscosity and the adhesivestrength, the adhesive strength of the base, a long time stickingproperties for the skin, a pain at the time of release, a rash on theskin and the like can greatly be improved.

Further, when two or more of polyisobutylenes with different viscosityaverage molecular weight are blended, it is preferable that the totalamount of the polyisobutylenes does not exceed 50% by mass based on thetotal amount of the base.

A preferable adhesive base related to the invention contains astyrene-isoprene-styrene block copolymer, polyisobutylene, a tackifierand a plasticizer, and after the styrene-isoprene-styrene blockcopolymer, polyisobutylene and the tackifier are mixed at a desirableratio, this mixture is adjusted to have the above viscosity by theplasticizer to obtain it. The adhesive strength of the patch of theinvention can be adjusted mainly by adjusting the composition of theadhesive base.

As tackifiers, preferably those with softening point of 60° C.-150° C.,for example, rosin esters, hydrogenated rosin esters, maleic aciddegenerated rosin esters, polyterpene resins and petroleum resins can beused, and specifically, Ester Gum A, AA-G, H or HP (manufactured byArakawa Chemical Industris, Ltd.), Hariester L, S or P (manufactured byHarima Chemicals Inc.), Pinecrystal KE-100 or KE-311 (manufactured byArakawa Kagaku Co., Ltd.), Hercolyn D (manufactured by Rika HerculesCo., Ltd.), Foral 85 or 105 (manufactured by Rika Hercules Co., Ltd.),Staybelite Ester 7 or 10 (manufactured by Rika Hercules Co., Ltd.),Pentalyn 4820 or 4740 (manufactured by Rika Hercules Co., Ltd.), ARKONP-85 or P-100 (manufactured by Arakawa Kagaku Co., Ltd.), Escorez 5300(manufactured by Exxon Chemical Co., Ltd.), Clearon K, M or P (YasuharaChemical Co., Ltd.) and the like are illustrated, and one or more ofthese can be blended in the adhesive base. The content of a tackifier ispreferably 5-50% by mass based on the total amount of the base, morepreferably 7-45% by mass, further preferably 10-40% by mass,. whereinthe viscosity and adhesive strength are adjusted in the above range. Bythis blend ratio are greatly improved the adhesive strength of theobtained base, sticking properties to the skin, a pain at the time ofrelease, a rash on the skin and the like.

As plasticizers, preferably those with solution viscosity of 10-100centistokes (40° C.), for example, almond oil, olive oil, camellia oil,persic oil, peanut oil, olefin acid and liquid paraffin are illustrated,and one or more of these can be blended in the adhesive base. The blendratio of a plasticizer is preferably 10-70% by mass based on the totalamount of the base, more preferably 15-60% by mass, further preferably20-55% by mass, wherein the viscosity and adhesive strength are adjustedin the above range. By this blend ratio are greatly improved theadhesive strength of the obtained base, sticking properties to the skin,a uniform dispersion of a drug in the base, a pain at the time ofrelease, a damage toward the horny layer, a rash on the skin, a thermalstability and the like.

The base of the patch of the invention may contain a filler, anantioxidant, an ultraviolet absorbent, a resolvent and the like. Asfillers, zinc oxide, aluminum oxide, titanium dioxide, calciumcarbonate, synthetic aluminum silicate, silica, magnesium oxide, metalsalts of stearic acid and the like are used. As antioxidants, forexample, ascorbic acid, tocopherol acetate, natural vitamin E, dibutylhydroxytoluene, propyl gallate and the like are used. As ultravioletabsorbents, for example, 2-hydroxy-4-methoxybenzophenone, glycolsalicylate, 2-(2-hydroxy-5-methylphenyl)benzotriazole and the like areused, though it is preferable not to be contained considering the safetyfor the skin. As resolvents, for example, oleic acid, benzyl alcohol,isopropyl myristate, crotamiton, oleyl alcohol, eucalyptus oil,limonene, isopulegol or other oils are used. In addition, a surfactant,a fat, a higher fatty acid, a flavoring agent and the like may becontained if necessary. Further, a skin irritant (counterirritant) suchas L-menthol, camphor, mentha oil, red pepper extract, capsaicin, benzylnicotinate, methyl salicylate or glycol salycilate can appropriately beblended if necessary.

In the following, a preparation method of the patch of the invention isexplained. As one example, first, a tackifier and a plasticizer areadded to styrene-isoprene-styrene block copolymer and polyisobutylene toadjust the viscosity and adhesive strength, followed optionally byaddition of a filler, an antioxidant and the like at a designated ratioto give a mixture. The mixture is heated under stirring in an atmosphereof nitrogen to give a melt. The temperature at the time of stirring is110-200° C., and the stirring period is 30-120 min. Then, an effectiveingredient is added to the above melt under stirring at 110-200° C. andmixed for 1-30 min to give a homogeneous melt. Next, the melt isdirectly spreaded on a backing which is specially treated with anultraviolet absorbent and/or an ultraviolet-shielding agent in a usualmanner, then covered with a releasable coat, or otherwise, after oncespreading on the releasable coat, a pressure transfer may be made bycovering with the backing. The releasable coat is appropriately selectedfrom a release paper which is carried out with a release treatment, acellophane, or a film such as polyethylene, polypropylene or polyester.

EXAMPLE

In the following, the invention is explained in more detail by theexamples. The invention, however, is not limited to these examples, andvarious changes may be made without departing from the spirit of theinvention. Further, in the examples, all % mean % by mass.

Tape Preparation 1 Example 1

Styrene-isoprene-styrene block copolymer (KRATON D-1107CU: manufacturedby Shell Chemical) of 22 parts by mass, polyisobutylene (Oppanol B80:manufactured by BASF) of 22 parts by mass, hydrogenated rosin ester(Staybelite Ester: manufactured by Rika Hercules) of 12 parts by mass,liquid paraffin (Crystol J-325; manufactured by Esso Petroleum) of 40parts by mass and dibutyl hydroxytoluene of 1 part of mass were heatedat 110-200° C. under a nitrogen atmosphere, added with ketoprofen of 3parts by mass under stirring, and further mixed for 5-30 min to obtain ahomogeneous melt which was made a tape base. Then, the base was spreadedon a polyester film treated with silicone to become 1 g per 70 cm².

In the meantime,2-(3-t-butyl-5-methyl-2-hydroxyphenyl)-5-chlorobenzotriazole(TINUVIN326: manufactured by Nagase Kasei) of 1 part by mass wasadsorbed to a polyester woven fabric of 99 parts by mass, in which theweight is about 110 g/cm², to obtain a backing with anultraviolet-shielding treatment. The spreaded base on the above film wascovered by this backing and allowed to a pressure transfer to give thetape preparation by cut in a desirable size.

Tape Preparation 2 Example 2

The ketoprofen tape preparation was obtained in the same way as that ofthe example 1 except adsorbing2-(3-t-butyl-5-methyl-2-hydroxyphenyl)-5-chlorobenzotriazole(TINUVIN326: manufactured by Nagase Kasei) of 2 parts by mass to thepolyester woven fabric of 98 parts by mass and obtaining a backing withan ultraviolet-shielding treatment.

Tape Preparation 3 Example 3

The ketoprofen tape preparation was obtained in the same way as that ofthe example 1 except adsorbing2-(3-t-butyl-5-methyl-2-hydroxyphenyl)-5-chlorobenzotriazole(TINUVIN326: manufactured by Nagase Kasei) of 3 parts by mass to thepolyester woven fabric of 97 parts by mass and obtaining a backing withan ultraviolet-shielding treatment.

Tape Preparation 4 Example 4

The ketoprofen tape preparation was obtained in the same way as that ofthe example 1 except adsorbing2-(3-t-butyl-5-methyl-2-hydroxyphenyl)-5-chlorobenzotriazole(TINUVIN326: manufactured by Nagase Kasei) of 1 part by mass to a wovenfabric in which a polyester resin of 97.5 parts by mass was incorporatedwith titanium oxide of 1.5 parts by mass, and obtaining a backing withan ultraviolet-shielding treatment.

Tape Preparation 5 Example 5

The ketoprofen tape preparation was obtained in the same way as that ofthe example 1 except adsorbing2-(3-t-butyl-5-methyl-2-hydroxyphenyl)-5-chlorobenzotriazole(TINUVIN326: manufactured by Nagase Kasei) of 2 parts by mass to a wovenfabric in which a polyester resin of 96.5 parts by mass was incorporatedwith titanium oxide of 1.5 parts by mass, and obtaining a backing withan ultraviolet-shielding treatment.

Tape Preparation 6 Example 6

The ketoprofen tape preparation was obtained in the same way as that ofthe example 1 except adsorbing2-(3-t-butyl-5-methyl-2-hydroxyphenyl)-5-chlorobenzotriazole(TINUVIN326: manufactured by Nagase Kasei) of 2 parts by mass to a wovenfabric in which a polyester resin of 97.9 parts by mass was incorporatedwith titanium oxide of 0.1 parts by mass, and obtaining a backing withan ultraviolet-shielding treatment.

Tape Preparation 7 Example 7

The ketoprofen tape preparation was obtained in the same way as that ofthe example 1 except adsorbing2-(3-t-butyl-5-methyl-2-hydroxyphenyl)-5-chlorobenzotriazole(TINUVIN326: manufactured by Nagase Kasei) of 2 parts by mass to a wovenfabric in which a polyester resin of 97.8 parts by mass was incorporatedwith titanium oxide of 0.2 parts by mass, and obtaining a backing withan ultraviolet-shielding treatment.

Tape Preparation 8 Comparative Examples 1, 3

The ketoprofen tape preparation was obtained in the same way as that ofthe example 1 except no ultraviolet-shielding treatment to the polyesterwoven fabric (no treatment).

Tape Preparation 9 Comparative Example 2

The ketoprofen tape preparation was obtained in the same way as that ofthe example 2 except changing the ultraviolet absorbent used in theultraviolet-shielding treatment for the polyester woven fabric into2-(2′-hydroxy-5′-methylphenyl)benzotriazole.

Photo-Transmission Test

As for each backing used in the tape preparations 1-9 (Examples 1-7 andComparative examples 1-3), the photo-transmission tests were carriedout. First, an ultraviolet intensity was measured under a directsunlight by an ultraviolet intensity meter (Topcon Co., Ltd., UVR-2). Atthis time, UD-36 was used for a receiving part, and the measuring wavelength was 310-400 nm. Then, an ultraviolet dose transmitting throughthe backing was measured under a circumstance in which a direct sunlightirradiated enough to each backing, and when the ultraviolet intesity(Examples 1-5, Comparative examples 1 and 2, about 3.0 mW/cm²; Examples6-7, Comparative example 3, about 1.6 mW/cm²) without the above backingwas made 100, the ultraviolet transmittances were calculated for thephoto-transmission tests.

Photo-Stability Test 1

As for each of the tape preparations 1-9 (Examples 1-7 and Comparativeexamples 1-3), the photo-stability test of the drug was carried out.Namely, the backing surface of each tape preparation was turned upwardand let stand at a place where a direct sunlight irradiated enough,whereby a drug remaining ratio in the base was measured by liquidchromatography. Further, a daytime (fine weather) ultraviolet dose inTosu-shi, Saga prefecture on Aug. 22, 2002 when the tests of Examples1-5 and Comparative examples 1 and 2 were carried out was about 10000mJ/cm² per hour, the irradiation time being 8 hours (accumulatedultraviolet dose, about 80000 mJ/cm²), and a daytime ultraviolet dose inTosu-shi, Saga prefecture on Nov. 5-6, 2002 when the tests of Examples 6and 7 and Comparative example 3 were carried out was about 6000 mJ/cm²per hour, the irradiation time being 15 hours (accumulated ultravioletdose, about 85000 mJ/cm²).

Photo-Stability Test 2

The backing surface of each tape preparation was turned upward and letstand at a place where a direct sunlight irradiated enough, and as tothe degree of coloring of the base after the tests (Examples 1-5,Comparative examples 1 and 2: ultraviolet dose, about 10000 mJ/cm² perhour; irradiation time, 8 hours; accumulated ultraviolet dose, about80000 mJ/cm², Examples 6 and 7, Comparative example 3: ultraviolet dose,about 6000 mJ/cm² per hour; irradiation time, 15 hours; accumulatedultraviolet dose, about 85000 mJ/cm²), the external appearance wasobserved.

Photo-Stability Test 3

The backing surface of each tape preparation was turned upward and letstand at a place where a direct sunlight irradiated enough, and as tothe agglutinative strength (stickiness) of the base after the tests(Examples 1-5, Comparative examples 1 and 2: ultraviolet dose, about10000 mJ/cm² per hour; irradiation time, 8 hours; accumulatedultraviolet dose, about 80000 mJ/cm², Examples 6 and 7, Comparativeexample 3: ultraviolet dose, about 6000 mJ/cm² per hour; irradiationtime, 15 hours; accumulated ultraviolet dose, about 85000 mJ/cm²), theexternal appearance was observed.

The results are summarized in Table 1. TABLE 1 Tape Drug contentUltraviolet Appearance Degradation of adhesive preparations after test(%) transmittance (%) change mass (stickiness) Example 1 Formula 1 90.81.92 no no Example 2 Formula 2 98.7 1.38 no no Example 3 Formula 3 99.90.67 no no Example 4 Formula 4 98.8 0.84 no no Example 5 Formula 5 100.00.44 no no Example 6 Formula 6 99.3 0.84 no no Example 7 Formula 7 99.50.67 no no Comparative Formula 8 53.0 24.8 yellow yes Example 1Comparative Formula 9 77.5 2.83 faint partly Example 2 yellow yesComparative Formula 8 49.8 24.8 yellow yes Example 3

Sensory Test

The tape preparation 5 (70 cm²) was adhered to knees of five volunteersfor 8 hours, and the sticking properties and the uncomfortable feelingwhen sticking were evaluated to carry out the total judgment.

Evaluation standard for useability

Sticking properties

No peeling off: ⊚ End part was peeled off: ◯ Not less than ¼ were peeledoff: Δ Not less than ½ were peeled off: ×

Uncomfortable feeling when sticking

No tightening feeling: ◯ Slight tightening feeling: Δ

Tightening feeling: ×

Total judgment

Satisfied with useablity: ◯ Partly dissatisfied with useablity: ΔDissatisfied with useablity: ×

The results were summarized in Table 2. TABLE 2 Useability UltravioletSticking Uncomfortable Weight transmit- proper- felling when Total(g/m²) tance (%) ties sticking judgment Tape 112.5 0.44 ⊚ ◯ ◯preparation

INDUSTRIAL APPLICABILITY

The patch of the invention is excellent in an ultraviolet-shieldingeffect, can lower an ultraviolet transmittance of a backing even whenexposed to the direct sunlight with a high ultraviolet dose, does notproduce degradation such as oozing of a pressure-sensitive adhesivelayer, etc., and can exhibit satisfactory drug effects. In addition,since an ultraviolet absorbent itself does not contact to the skin,irritation to the skin can be lowered, and therefore, the safety andalso the use feeling are excellent.

1. A patch comprising a polyester backing and a pressure-sensitive adhesive layer formed on one surface of the backing and containing a nonsteroidal anti-inflammatory drug (NSAID) wherein the backing contains a hydroxyphenylbenzotriazole derivative represented by the general formula (1):

wherein R₁ and R₂ are each independently hydrogen or C₁₋₈ alkyl; and X is halogen atom.
 2. The patch according to claim 1, wherein the backing contains further titanium oxide.
 3. The patch according to claim 1, wherein the ultraviolet transmittance of the backing is not more than 2%.
 4. The patch according to claim 1, wherein the weight of the backing is 100 g/m²-130 g/m².
 5. The patch according to claim 1, wherein the nonsteroidal anti-inflammatory drug (NSAID) is ketoprofen.
 6. The patch according to claim 1, wherein the pressure-sensitive adhesive layer consists of a styrene-isoprene-styrene block polymer and/or polyisobutylene.
 7. The patch according to claim 1, wherein the pressure-sensitive adhesive layer contains no ultraviolet absorbent. 